Utilize este identificador para referenciar este registo: http://hdl.handle.net/10400.17/1655
Título: Intravenous Immunoglobulin for the Treatment of Quetiapin-Induced Bullous Pemphigoid in an HIV-Infected Patient
Autor: Cabete, J
Santos, G
Páris, F
Serrão, V
Fidalgo, A
Palavras-chave: HSAC DER
HIV
Imunoglobulinas Intravenosas
Penfigoide Bolhoso
Data: 2013
Editora: Serviço de Dermatologia do Hospital dos Capuchos, Centro Hospitalar de Lisboa Central, EPE
Citação: IN: 71st Annual Meeting of the American Academy of Dermatology; 2013, Março. Miami, EUA
Resumo: The authors present the case of a 48-year-old woman with HIV-­associated dementia treated with antiretroviral therapy and psychoactive drugs, to whom bullous pemphigoid(BP) was diagnosed. Given incomplete response to corticotherapy, and azathioprine-­induced bicytopenia,intravenous immunoglobulin(IVIG) was initiated. Despite transient disease control, recurrent flares suggested a persistent triggering factor. Specifically, quetiapin was implicated and discontinued with an immediate clinical response. Inadvertent re-­challenge with olanzapine(a related drug)led to a new eruption, confirming drug-­induced BP (DIBP). A total of six IVIG cycles were completed, without severe side effects to report, namely HIV disease progression. HIV-­related autoimmune bullous diseases are rare. Treatment of severe drug eruptions is primarily based on immunossupressive drugs, raising concerns regarding additional immunossupression. This case suggests IVIG as a valuable option for the treatment of BP in HIV patients. In addition, quetiapin should be added to the list of neuroleptics previously linked to DIBP.
URI: http://hdl.handle.net/10400.17/1655
Aparece nas colecções:DER - Comunicações e Conferências

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
Intravenous immunog apres.pdf5,63 MBAdobe PDFVer/Abrir


FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.